Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus

Feng, Xuebing; Chen, W; Xiao, Liwei; Gu, Fei; Huang, Jing; Tsao, Betty P.; Sun, Lingyun

doi:10.1177/0961203316651738

Cited by 45 publications

(37 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arch Med Sci the major defect is a loss of self-tolerance, which results in the production of autoreactive lymphocytes [38]. In this study, we found that there was a significant association between MIF levels and SLEDAI scores (of both < 8 and ≥ 8) of SLE patients, and this finding is similar to Diaz Rizo et al [39] and Feng et al [28]. Our findings further revealed that disease duration in SLE patients for both year < 5 and year ≥ 5 had significantly higher plasma/ serum MIF levels, compared to healthy controls patients in a matched population.…”

supporting

confidence: 85%

“…The articles were subjected to screening, and 31 duplicate articles as well as 202 articles with reviewed titles and abstract were excluded. Twenty-two articles were retrieved for further detailed assessments, and 9 articles were further excluded (3 have no full texts, 3 have no available data, and 3 were only review papers), leaving 13 articles meeting the inclusion criteria [16][17][18][19][20][28][29][30][31][32][33] (Figure 1). Among the 13 included articles, 5, 3, 1, and 1 were from PubMed [16,18,20,28,29,32], Embase [17,30,31], Web of Science [19], and several Chinese databases [33], respectively.…”

Section: Literature Searchmentioning

confidence: 99%

See 1 more Smart Citation

Levels of the macrophage migration inhibitory factor and polymorphisms in systemic lupus erythematosus: a meta-analysis

et al. 2021

View full text Add to dashboard Cite

IntroductionSeveral published results have established variations in respect to plasma/serum macrophage migration inhibitory factor (MIF) levels and gene polymorphisms with systemic lupus erythematosus (SLE). This study gave a more concise estimation on the MIF levels for SLE patients and established the association between MIF polymorphisms and SLE.Material and methodsAll articles were searched from PubMed, Embase, Web of Science, Wan-Fang, Chinese Biological Medical Literature, and China National Knowledge Infrastructure up to 6th October 2017, with no language restriction. Pooled standard mean difference with 95% conﬁdence interval was evaluated using random effect model. Thirteen articles were used for this meta-analysis, with 620 SLE patients and 779 healthy controls assessed for MIF levels, and 2,159 SLE patients and 2,574 healthy controls considered for MIF-173 C/G and MIF-794 CATT polymorphisms.ResultsThere was a significant higher MIF levels in SLE patients than in healthy controls (p = 0.004). The subgroup analysis showed Asians and ages < 30 had higher MIF levels in SLE patients than in healthy controls. It was evident that patients with systemic lupus erythematosus diseases activity index scores < 8 and ≥ 8, and disease duration for both year < 5 and ≥ 5 of SLE had higher MIF levels when compared to healthy controls. We found a signiﬁcant association between SLE and MIF-173 C/G, but not MIF-794 CATT.ConclusionsThis study provided evidence of significant higher MIF levels in SLE patients and supported the association of MIF-173 C/G and SLE. However, we were not able to establish an association between MIF-794 CATT and SLE.

show abstract

supporting

confidence: 85%

Section: Literature Searchmentioning

confidence: 99%

Levels of the macrophage migration inhibitory factor and polymorphisms in systemic lupus erythematosus: a meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…MIF has been reported to play a role in SLE pathogenesis,3 as it is associated with disease activity, organ damage and glucocorticoid use 3, 17, 18. Our analysis revealed that serum MIF was 3.5 times higher in SSc patients than in SLE patients.…”

Section: Discussionmentioning

confidence: 57%

“…MIF has been reported to play a role in SLE pathogenesis, 3 as it is associated with disease activity, organ damage and glucocorticoid use. 3,17,18 Our analysis revealed that serum MIF was 3.5 times higher in SSc patients than in SLE patients. This may suggest that while MIF not only can play a pathogenic role in inflammatory autoimmune diseases, such as SLE, but may also play a part in diseases that have a prominent fibrotic phase, such as that seen in SSc.…”

Section: Discussionmentioning

confidence: 67%

Analysis of serum macrophage migration inhibitory factor and D‐dopachrome tautomerase in systemic sclerosis

et al. 2018

View full text Add to dashboard Cite

ObjectivesMacrophage migration inhibitory factor (MIF) and D‐dopachrome tautomerase (DDT), members of the same cytokine superfamily, are linked to the pathogenesis of a number of inflammatory diseases. The aim of this study was to investigate their clinical relevance in systemic sclerosis (SSc).MethodsSerum MIF and DDT were quantified in 105 SSc patients by ELISA and levels compared to healthy controls (HC) (47) and patients with systemic lupus erythematosus (SLE) (184). Clinical parameters included organ involvement, serum laboratory markers and results of pulmonary function tests, and overall disease activity assessed using the European Scleroderma Trials and Research group (EUSTAR) activity index.ResultsThere was no significant difference in serum DDT concentrations between patients with SSc and HC. However, serum MIF was significantly increased in SSc compared to both HC and SLE cohorts. Serum MIF was increased in SSc patients with low forced vital capacity (FVC) and was also associated with the use of angiotensin II receptor blockers and beta blockers in SSc, confirmed after adjusting for the presence of systemic hypertension and low FVC. Serum DDT was significantly higher in SSc patients with low FEV1 and negatively correlated with EUSTAR score, particularly in patients with limited disease.ConclusionAlthough not significantly linked to specific clinical parameters, serum MIF was significantly higher in SSc patients than in HC and SLE patients, suggesting a fundamental role for MIF in SSc. DDT, while closely related to MIF, did not show a similar expression profile, suggesting functional differences between these molecules.

show abstract

“…Numerous studies have revealed that the immunoregulatory cytokine MIF participates in the pathogenesis of SLE with respect to both disease initiation and progression [7]. MIF expression is increased in SLE patients and positively correlates with disease activity [8]. MIF is overexpressed in lupus-prone mice and renal injury is alleviated in Mif −/− MRL/lpr mice [9].…”

Section: Introductionmentioning

confidence: 99%

Macrophage Migration Inhibitory Factor deficiency attenuates kidney Injury by downregulating cytokines via CYR61 in lupus-prone mice induced by pristane.

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematous (SLE) and accounts for significant mortality and morbidity. Previous research has demonstrated that macrophage migration inhibitory factor (MIF) is involved in the pathogenesis of lupus nephritis, but the detailed mechanism is not elucidated. The aim of this study was to explore the pathogenesis of MIF in lupus nephritis with the pristane-induced mouse model of SLE. Methods Mif-/- mice and Wild type mice in the C57BL/6 (B6) background were used to induce Lupus model by pristane. 24 hour urine and sera were collected in the sixth month and mice were sacrificed to harvest tissues. Serum ANA, anti-dsDNA antibodies, C3, urinary creatinine and albumin were detected by ELISA. Related inflammatory cytokines were detected by Bio-Plex Pro™ assays and ELISA. CYR61 mRNA expression was detected by RT-qPCR and CYR61 protein expression were detected by Western blot. Immunofluorescence was used to detect the expression of MIF, ICs and C3 deposition and related cytokines expression in the kidneys. Immunohistochemical staining was used to detect macrophage infiltration and periodic acid-Schiff (PAS) staining were used for kidney histology. The Mann-Whitney test and Student’s t test were used to compare multiple group differences. The correlation were analyzed by Spearman correlation. Results Mif -/- mice with pristane-induced SLE have less inflammatory cytokines expression in sera. The Mif-/- mice have reduced renal injury, less macrophage infiltration, CYR61 and inflammatory cytokines expression in the kidneys. MIF induced the expression of CYR61, which can induce the expression of IL-1β, IL-6 and MCP-1 in bone marrow-derived macrophages (BMDM) in a cell-based assay. Conclusions The results suggest that MIF plays an important role in kidney injury by inducing macrophages infiltration and inflammatory cytokines expression in situ. Our finding support the pathogenic contribution of high expression MIF alleles in SLE and suggest that MIF antagonism might offer an effective therapeutic option in lupus nephritis.

show abstract

Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus

Cited by 45 publications

References 39 publications

Levels of the macrophage migration inhibitory factor and polymorphisms in systemic lupus erythematosus: a meta-analysis

Levels of the macrophage migration inhibitory factor and polymorphisms in systemic lupus erythematosus: a meta-analysis

Analysis of serum macrophage migration inhibitory factor and D‐dopachrome tautomerase in systemic sclerosis

Macrophage Migration Inhibitory Factor deficiency attenuates kidney Injury by downregulating cytokines via CYR61 in lupus-prone mice induced by pristane.

Contact Info

Product

Resources

About